Page 967 - Read Online

Brodosi et al. Hepatoma Res 2020;6:82 I http://dx.doi.org/10.20517/2394-5079.2020.88 Page 11 of 11

86. Del Prato S. Heterogeneity of diabetes: heralding the era of precision medicine. Lancet Diab Endocrinol 2019;7:659-61.
87. Tricco AC, Antony J, Soobiah C, et al. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting
insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis. Syst Rev 2013;2:47.
88. Liu ST, Su KQ, Zhang LH, Liu MH, Zhao WX. Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: a
protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e21568.
89. MacIsaac RJ. Dulaglutide and insulin: how can the AWARD studies help guide clinical practice? Diabetes Ther 2020;11:1627-38.
90. Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Al-Ozairi E, Jayyousi A. Combination therapy with pioglitazone/exenatide
improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2
diabetes: a 3-year follow-up of the Qatar study. Diabetes Obes Metab 2020; doi: 10.1111/dom.14153.
91. Vilsbøll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M. Dapagliflozin plus saxagliptin add-on therapy compared with
insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial.
Diabetes Care 2019;42:1464-72.
92. Zaccardi F, Dhalwani NN, Dales J, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic
review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:985-97.
93. Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with
chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diab Endocrinol 2020;8:582-93.
94. Papazafiropoulou AK, Melidonis A, Antonopoulos S. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose
cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes. Curr Pharm Des 2020; doi: 10.2174/138161
2826666200909142126.
95. Vincent RK, Williams DM, Evans M. A look to the future in non-alcoholic fatty liver disease: are glucagon-like peptide-1 analogues or
sodium-glucose co-transporter-2 inhibitors the answer? Diabetes Obes Metab 2020; doi: 10.1111/dom.14196.
96. Brodosi L, Marchignoli F, Petroni ML, Marchesini G. NASH: a glance at the landscape of pharmacological treatment. Ann Hepatol
2016;15:673-81.